CellCentric
To add a bio or update company history, please click update information.
News from CellCentric
CellCentric
6 May 2026
CellCentric raises a £160m Series D led by Venrock Healthcare Capital Partners for oral drug designed to treat multiple myeloma and other cancers
CellCentric develops inobrodib, an oral drug designed to treat multiple myeloma and other cancers. The treatment is intended to provide a new option for patients, including those who have already undergone multiple lines of therapy.
CellCentric
19 May 2025
CellCentric raises £90m Series C led by RA Capital and Forbion to advance first-in-class cancer drug
CellCentric is developing an oral cancer drug for multiple myeloma that targets a novel biological pathway, with ongoing clinical studies evaluating its use alone and in combination with existing therapies.
CellCentric
- Life Sciences
- Cambridge, United Kingdom
- £250m
- cellcentric.com
- Update Information
More venture news
- 3 Jun 2026
ApohaApoha unlocks £27m in funding led by Singular to measure how molecules and materials behave under real-world conditions
EquityLife Sciences - 2 Jun 2026
IMU BiosciencesIMU Biosciences unlocks £40m Series A led by IQ Capital and Molten Ventures to decode the immune system with high-resolution blood analysis
Series ALife Sciences - 28 May 2026
PercepticPerceptic raises a £9m seed round led by Accel to unify drug discovery and development on a single AI platform
SeedLife Sciences
